Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

THE TRUTH ABOUT: Abcl - Caught on Camera

AbCellera Biologics Bets on Hot Flash Antibody as Pipeline Pivot Gains Steam

AbCellera Biologics (NASDAQ:ABCL) is emphasizing its transition from a partner-based antibody discovery business to a proprietary drug development company, Chief Financial Officer Andrew Booth said during a company presentation focused on the biotech’s pipeline and lead clinical program. Booth said

MarketBeat

AbCellera Biologics Q1 Earnings Call Highlights

AbCellera Biologics (NASDAQ:ABCL) said its first quarter of 2026 was marked by progress in its internal drug pipeline, including interim Phase 1 data for its lead program, ABCL635, and continued preparation for multiple clinical catalysts expected over the next two years. President and CEO Dr. Carl

MarketBeat

3 New Stocks SoftBank Is Betting Big on in 2026

SoftBank revealed new positions in each of these three companies.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Why Did AbCellera's Stock Jump Over 7% After Hours?

AbCellera Biologics Inc. (NASDAQ:ABCL) shares are trading on Thursday.

Benzinga

Should You Follow Insider Buying on This Biotech Penny Stock?

With significant insider purchases and high-profile hedge fund interest, AbCellera is one penny stock to watch.

Barchart

3 AI-Driven Drug Stocks to Buy Before They Breakout

The pharma sector is expected to undergo a huge disruption, thanks to the impact of artificial intelligence. Here are three companies that Wall Street analysts think could benefit, based on their AI-driven R&D.

Barchart

3 Stocks With Upside Potential in the Near Term

The record-high inflation, the Federal Reserve’s hawkish tilt, and growing recession fears have led to heightened volatility in the market. However, despite the concerning macro environment, Wall Street analysts see upside potential in VEON (VEON), Lumen Technologies (LUMN), and AbCellera Biologics (ABCL). So, these stocks could be worth adding to…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Aditya Birla Capital profit after tax rises 20% to Rs 450 crore

NEW DELHI: Aditya Birla Capital on Thursday reported a rise of 20 per cent in its consolidated profit after tax at Rs 450 crore in quarter ended March 2022.

The Times of India

What 4 Analyst Ratings Have To Say About AbCellera Biologics

Over the past 3 months, 4 analysts have published their opinion on AbCellera Biologics (NASDAQ:ABCL) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

People

Mangeet Kaur BounsMangeet

595 stories

Andrew Booth

29 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Lumen Technologies Inc

12 stories

AbCellera Biologics

10 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.